Clinical Trials at Providence Portland Medical Center

As of June 2026, 128 paid clinical trials are recruiting at Providence Portland Medical Center, located at 5050 NE HOYT ST, SUITE 155, PORTLAND, OR 97213-2991, phone (503) 215-6819 in Portland, Oregon. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: June 12, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

128 clinical trials at Providence Portland Medical Center

·Clear filters·↓ Download CSV

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

for Acute Myeloid Leukemia

211 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18 - 59

Code: NCT05554406·Phase 2·Recruiting

Apply to this trial

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

for Acute Myeloid Leukemia

Drug: Venetoclax

167 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18 - 59

Code: NCT05554393·Phase 2·Recruiting

Apply to this trial

Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

for Refractory Differentiated Thyroid Gland Carcinoma

301 locations incl. Anchorage

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All·Age: 18+

Code: NCT06475989·Phase 3·Recruiting

Apply to this trial

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

for Recurrent Lung Non-Small Cell Carcinoma

266 locations incl. Daphne

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18 Minutes+

Code: NCT06031688·Phase 2·Recruiting

Apply to this trial

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

for Metastatic Nasopharyngeal Carcinoma

Drug: Relatlimab

83 locations incl. Dublin

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06029270·Phase 2·Recruiting

Apply to this trial

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

for AL Amyloidosis

117 locations incl. Goodyear

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT06022939·Phase 3·Recruiting

Apply to this trial

Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer

for Rectal Cancer

101 locations incl. Phoenix

Sponsor: Canadian Cancer Trials Group

Sex: All·Age: 18+

Code: NCT06205485·Phase 3·Recruiting

Apply to this trial

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

for Advanced Esophageal Adenocarcinoma

Drug: Nivolumab

371 locations incl. Little Rock

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06203600·Phase 2, Phase 3·Recruiting

Apply to this trial

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

for Triple-Negative Breast Cancer

88 locations incl. Mobile

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06393374·Phase 3·Recruiting

Apply to this trial

A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma

for Glioblastoma

Drug: Niraparib

32 locations incl. Birmingham

Sponsor: Ivy Brain Tumor Center

Sex: All·Age: 18+

Code: NCT06388733·Phase 3·Recruiting

Apply to this trial

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

for Acute Myeloid Leukemia

335 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05564390·Phase 2·Recruiting

Apply to this trial

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

for Small Cell Lung Cancer

30 locations incl. Springdale

Sponsor: Daiichi Sankyo

Sex: All·Age: 18+

Code: NCT06203210·Phase 3·Recruiting

Apply to this trial

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

for Malignant Female Reproductive System Neoplasm

186 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06126276·Phase 2·Recruiting

Apply to this trial

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

for Breast Neoplasms

46 locations incl. Chandler

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06312176·Phase 3·Recruiting

Apply to this trial

Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

for Prostate Adenocarcinoma

133 locations incl. Anchorage

Sponsor: SWOG Cancer Research Network

Sex: Male·Age: 18+

Code: NCT05806515·Phase 2·Recruiting

Apply to this trial

Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors

for Breast Cancer

673 locations incl. Anchorage

Sponsor: NRG Oncology

Sex: All·Age: 18 - 100

Code: NCT05896189·Recruiting

Apply to this trial

GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma

for Metastatic Melanoma

1 location in Portland

Sponsor: Providence Health & Services

Sex: All·Age: 18+

Code: NCT05913388·Phase 2·Recruiting

Apply to this trial

Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)

for Malignant Solid Neoplasm

384 locations incl. Anchorage

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All·Age: All ages·Accepts healthy volunteers

Code: NCT06295367·Recruiting

Apply to this trial

A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors

for Advanced Solid Tumor

20 locations incl. Irvine

Sponsor: Daiichi Sankyo

Sex: All·Age: 18+

Code: NCT06244485·Phase 1·Recruiting

Apply to this trial

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

for Endometrial Cancer

17 locations incl. Birmingham

Sponsor: SystImmune Inc.

Sex: All·Age: 18+

Code: NCT06293898·Phase 1·Recruiting

Apply to this trial

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

for Muscle Invasive Bladder Urothelial Carcinoma

490 locations incl. Phoenix

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05987241·Phase 2, Phase 3·Recruiting

Apply to this trial

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

for Carcinoma, Non-Small-Cell Lung

Drug: LY3537982

91 locations incl. Huntsville

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06119581·Phase 3·Recruiting

Apply to this trial

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

for Prostate Adenocarcinoma

388 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: Male·Age: 18+

Code: NCT05946213·Phase 3·Recruiting

Apply to this trial

LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia

for Advanced Colorectal Carcinoma

225 locations incl. Fort Smith

Sponsor: University of Rochester

Sex: All·Age: 18+

Code: NCT06073431·Recruiting

Apply to this trial

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

for Anatomic Stage II Breast Cancer AJCC v8

Drug: Durvalumab

536 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06058377·Phase 3·Recruiting

Apply to this trial

A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer

for Carcinoma, Non-small-Cell Lung

7 locations incl. Newnan

Sponsor: Johnson & Johnson Enterprise Innovation Inc.

Sex: All·Age: 18+

Code: NCT06116786·Phase 1·Recruiting

Apply to this trial

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

for Mantle Cell Lymphoma

237 locations incl. Little Rock

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 60+

Code: NCT05976763·Phase 3·Recruiting

Apply to this trial

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

for Breast Cancer

1208 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: Female·Age: 18 - 60

Code: NCT05879926·Phase 3·Recruiting

Apply to this trial

Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors

for Hodgkin Lymphoma

428 locations incl. Anchorage

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All·Age: 18+

Code: NCT06002828·Recruiting

Apply to this trial

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

for Plasma Cell Myeloma

397 locations incl. Anchorage

Sponsor: SWOG Cancer Research Network

Sex: All·Age: All ages

Code: NCT05561387·Phase 3·Recruiting

Apply to this trial

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

for Grade 3b Follicular Lymphoma

104 locations incl. Tucson

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT05890352·Phase 2·Recruiting

Apply to this trial

A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

for Advanced Solid Tumor

9 locations incl. Duarte

Sponsor: BeOne Medicines

Sex: All·Age: 18+

Code: NCT05981703·Phase 1·Recruiting

Apply to this trial

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

for Anatomic Stage I Breast Cancer AJCC v8

955 locations incl. Birmingham

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT05929768·Phase 3·Recruiting

Apply to this trial

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

for Small Cell Lung Cancer (SCLC)

12 locations incl. Duarte

Sponsor: Phanes Therapeutics

Sex: All·Age: 18+

Code: NCT05652686·Phase 1, Phase 2·Recruiting

Apply to this trial

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

for Anatomic Stage II Breast Cancer AJCC v8

820 locations incl. Birmingham

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT05812807·Phase 3·Recruiting

Apply to this trial

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

for Diffuse Large B-Cell Lymphoma

87 locations incl. Tucson

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT05633615·Phase 2·Recruiting

Apply to this trial

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

for Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

Drug: Nivolumab

390 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 5 - 60

Code: NCT05675410·Phase 3·Recruiting

Apply to this trial

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

for Recurrent Lung Non-Small Cell Carcinoma

454 locations incl. Daphne

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT05642572·Phase 2·Recruiting

Apply to this trial

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

for Recurrent Endometrial Carcinoma

Drug: Selumetinib

293 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: Female·Age: 18+

Code: NCT05554328·Phase 2·Recruiting

Apply to this trial

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

for Advanced Malignant Solid Neoplasm

475 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: All ages

Code: NCT05564377·Phase 2·Recruiting

Apply to this trial